CSF3 and non-Hodgkin lymphoma: A previous study showed that the supplementation of plerixafor in a G-CSF–based regimen increased the percentage of CD38– cells in the circulating CD133+/CD34+ population within individual MM and NHL patients60 and another study reported elevated percentages of CD133+/CD38– within CD34+ cells if plerixafor was added to G-CSF instead of cyclophosphamide.61 Together these data show that the different mobilizing mechanisms of plerixafor and G-CSF cause the collection of different HC subset combinations.